PharmaEssentia

Company snapshot

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology, and immunology. Founded in 2003, PharmaEssentia is now expanding its global presence with operations in the U.S., Japan, China and Korea.

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PharmaEssentia. Not investment advice.

• What is PharmaEssentia?

  PharmaEssentia is a pharma organization headquartered in CN. Primary therapeutic focus areas include Polycythemia Vera (PV), Primary Myelofibrosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalT

• Is PharmaEssentia publicly traded?

  PharmaEssentia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does PharmaEssentia develop or market?

  We link 3 drug profile(s) where PharmaEssentia is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pharmaessentia#company-drugs.

• What are the latest developments for PharmaEssentia?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does PharmaEssentia focus on?

  PharmaEssentia focuses on Polycythemia Vera (PV), Primary Myelofibrosis based on our analysis of their pipeline programs and drug development activities.